TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an update.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced the appointment of Mr. Zhu Guoxin as the new senior vice president. Mr. Zhu brings over 30 years of leadership experience in global drug discovery and development, having previously served as vice president at Eli Lilly. This strategic appointment aims to enhance the company’s operational capabilities and support its growth in the pharmaceutical industry.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$86.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading pharmaceutical company based in China, primarily engaged in the research, development, manufacturing, and sales of a wide range of pharmaceutical products. The company focuses on various therapeutic areas including diabetes, obesity, immunology, neurological disorders, pain management, and oncology.
Average Trading Volume: 4,353,129
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$451.2B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.